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tients refusing treatment received high-dose chemothera-
py with PBSC rescue leading to grade IV hematologic 
toxicity without severe infections in all patients. No toxic 
death occurred. After a median follow-up time of 30 months, 
the median progression-free time was 12 months and sur-
vival time was 22 months for the entire group. By intent-to-
treat analysis the probability of 5-year progression-free sur-
vival was significantly higher for patients allocated to HD-ICE 
compared to patients receiving second-line chemotherapy 
after failure of AI-G (14 vs. 3%; p = 0.003). The estimated 5-
year overall survival between the 2 groups was different 
(27% vs. not reached) but did not reach significance (p = 
0.08).  Conclusion: HD-ICE is feasible and promising in pa-
tients with chemosensitive MSTS. A randomized phase III 
trial is warranted to further define the role of HD-ICE as con-
solidation treatment in these patients. 
 Copyright © 2006 S. Karger AG, Basel 
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 Abstract 
 Background: Prognosis of patients with metastatic soft tis-
sue sarcomas (MSTS) is poor even after response to doxoru-
bicin-based chemotherapy. We report phase II data of high-
dose chemotherapy and peripheral blood stem cell (PBSC) 
rescue in patients with MSTS responding to AI-G chemo-
therapy.  Patients and Methods: From 1997 to 2002, 55 pa-
tients with MSTS were prospectively treated with 4 cycles of 
AI-G (doxorubicin 75 mg/m 2 , ifosfamide 6 g/m 2  with G-CSF 
support). Responders received 2 further cycles of AI-G with 
collection of PBSCs. High-dose chemotherapy consisted of 
ifosfamide 12 g/m 2 , carboplatin 1.2 g/m 2  and etoposide 1.2 
g/m 2  (HD-ICE) followed by reinfusion of PBSCs.  Results: 
Twenty-one of 55 patients (38%) were assessed as respond-
ers (3 complete response, 18 partial response). All but 2 pa-
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 Introduction 
 Patients with metastatic soft tissue sarcomas (MSTS) 
have a poor prognosis with response rates to doxorubi-
cin-based chemotherapy between 23 and 45% and a me-
dian overall survival (OS) of about 11.7–15 months  [1–4] . 
As single agents, doxorubicin, ifosfamide and dacarba-
zine were shown to be most active in soft tissue sarcomas 
(STS) with an overall response rate between 15 and 28% 
 [5–8] . For the combination of doxorubicin and ifos-
famide, dose-dependent activities were shown  [9, 10] . In 
a phase II trial of the EORTC Soft Tissue and Bone Sar-
coma Group using doxorubicin 75 mg/m 2  and ifosfamide 
5 g/m 2 , a response rate of 45% was reached leading to a 
median survival of 15 months  [1] . This promising result 
could not be confirmed in a phase III trial with a response 
rate of only 23% and a median OS of 13 months  [2] . The 
most recent EORTC trial in MSTS randomizes between 
doxorubicin 75 mg/m 2  and a dose-intensified combina-
tion (doxorubicin 75 mg/m 2  and ifosfamide 10 g/m 2 ) to 
answer the question whether combination chemotherapy 
provides a survival advantage over single-agent doxoru-
bicin. As the use of hematopoietic growth factors allows 
safe escalation of dose, several regimes have been tested 
in patients with metastatic disease. These trials included 
small numbers of patients with a variety of bone sarco-
mas and STS  [11–14] . Furthermore, high-dose chemo-
therapy with autologous peripheral blood stem cell res-
cue (PBSCR) was performed in 18 patients with STS re-
ceiving doxorubicin and escalated doses of ifosfamide. 
The overall response rate was 50%, but OS was only 13 
months  [15] . In another series including 27 patients treat-
ed with epirubicin and ifosfamide, the overall response 
rate was 38%  [16] . A French protocol used etoposide, cis-
platin and ifosfamide in 30 patients with MSTS and while 
observing high renal toxicity, progression-free survival 
(PFS) was 21% at 5 years  [17] . In order to better define the 
role of a similar regimen including ifosfamide, carbopla-
tin and etoposide (ICE) with respect to both toxicity and 
efficacy, we performed a phase II trial in patients with 
MSTS responding to doxorubicin/ifosfamide induction 
chemotherapy supported by G-CSF (AI-G).
 Patients and Methods 
 Patients’ Eligibility 
 Patients between 18 and 60 years with histologically confirmed 
chemonaive MSTS of grade II and III with measurable disease were 
eligible for this phase II trial. Patients were required to have a good 
performance status (grade 0–2 according to WHO) and normal 
organ functions. Baseline eligibility criteria were normal blood 
counts (WBC  1 4,000/  l, platelet count  1 100,000/  l) and adequate 
renal (serum creatinine  ! 1.5 mg/dl) and liver (serum bilirubin  ! 1.5 
mg/dl) function tests. Patients with a history of active cardiac dis-
ease, including myocardial infarction and congestive heart disease, 
were excluded from the study. Further exclusion criteria included 
histology of malignant mesothelioma, nonmesenchymal chondro-
sarcoma, neuroblastoma, chordoma, Kaposi’s sarcoma and gastro-
intestinal stromal tumor, as well as a history of another malignan-
cy, central nervous system involvement and prior radiotherapy on 
parameter lesions. The study was performed according to the 
guidelines established by the Helsinki Declaration. The protocol 
was approved by the Ethics Committee of the Ludwig Maximilian 
University, Germany (No. 93/97). Written informed consent was 
obtained from all patients enrolled onto this study.
 Treatment 
 Induction chemotherapy consisted of doxorubicin 75 mg/m 2  as 
30 min infusion on day 1 and ifosfamide 1.5 g/m 2  as 120 min infu-
sion on days 1–4 (AI-G). Twenty-four hours after the end of che-
motherapy, G-CSF was given subcutaneously at a dose of 5   g/kg 
body weight/day until neutrophil counts exceeded 3,000/  l. 
AI-G cycles were repeated on day 22. After 4 cycles, responding 
patients received 2 further cycles of AI-G chemotherapy with an 
increased dose of G-CSF (10   g/kg body weight/day). If more than 
10 CD34+ cells/  l were found in peripheral blood, leukapheresis 
was performed to harvest at least 2  ! 10 6  CD34+ cells/kg body 
weight for autologous stem cell transplantation. The interval be-
tween the end of induction therapy or surgery and the start of 
high-dose chemotherapy was 4 weeks according to protocol. High-
dose chemotherapy consisted of ifosfamide 2 g/m 2  (1 h infusion) 
from day –8 until day –3, carboplatin 200 mg/m 2  (1 h infusion) 
from day –8 until day –3 and etoposide 200 mg/m 2  (22 h infusion) 
from day –8 until day –3 (HD-ICE). This resulted in total doses of 
12 g/m 2  ifosfamide, 1,200 mg/m 2  carboplatin and 1,200 mg/m 2  
etoposide. After 2 days without chemotherapy, patients received at 
least 2  ! 10 6  CD34+ cells/kg body weight via central venous cath-
eter on day 0. G-CSF (5   g/kg body weight) was given subcutane-
ously from day 1 until recovery of neutrophils. 
 Staging Procedures and Treatment Evaluation 
 At enrollment, physical examination, full laboratory analysis 
of blood parameters, creatinine clearance and cardiac ultrasound 
were performed. Additionally, contrast-enhanced CT scan of 
chest and abdomen and, if needed, MRI of the site of disease were 
performed. During induction treatment, blood counts, physical 
examination and toxicity assessment were performed after each 
cycle of AI-G chemotherapy. After 4 cycles, all patients were eval-
uated for response according to WHO criteria by contrast-en-
hanced CT scans, MRI, or both, based on the extent of the disease 
defined at presentation  [18] . Two independent investigators re-
viewed the files and films of all responding patients. Toxicity was 
evaluated according to the Common Toxicity Criteria  [19] . Before 
the start of high-dose chemotherapy, possible infections were ex-
cluded and serological blood tests were taken. During follow-up, 
staging was repeated every 3 months in the first year and every 6 
months thereafter.
 The duration of response was measured from the start of in-
duction treatment to the date of documented progression; the du-
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ration of complete response (CR) was calculated from the mo-
ment CR was documented to the first evidence of progression. 
PFS was measured from the date of treatment start to document-
ed progression. Survival was calculated from the time of treat-
ment start to the date of death. 
 The primary endpoint was PFS. Secondary endpoints were re-
sponse to induction chemotherapy and OS. 
 Statistics 
 OS and PFS were estimated according to the method of Kaplan 
and Meier  [20] . The 95% confidence intervals (CIs) of the Kaplan-
Meier estimates were calculated with Greenwood’s variances  [21] . 
The endpoints for actuarial analysis were PFS and OS. The com-
parison of survival parameters in responding versus nonrespond-
ing patients was performed using the log-rank test  [22] . For all 
tests, p  ! 0.05 was considered to be statistically significant.
 This protocol was designed as multicenter, nonrandomized, 
controlled single arm phase II study with PFS as primary end-
point. Sample size estimation for patients with MSTS was per-
formed for the improvement in PFS from 12 to 24 months by the 
log-rank test. The estimated response rate was 34% (23–45%). In 
case of 5.5 years of recruitment and 5-year follow-up, the required 
number was estimated as 53 patients (  = 5%,   = 20%).
 Results 
 Patients’ Characteristics 
 Between April 1997 and December 2002, 55 patients 
with MSTS were treated according to the protocol. The 
study population consisted of 34 male and 21 female pa-
tients with a median age of 40.5 years (range 18.8–60.5 
years). Details are shown in  tables 1 ,  2 . 
 Feasibility and Toxicity of Induction Chemotherapy 
(AI-G) 
 Forty-six patients (84%) received 4 induction chemo-
therapy cycles (AI-G) according to the study protocol. 
One patient refused further treatment after 1 cycle, 6 pa-
tients progressed after 2 cycles and 2 patients after 3 cy-
cles. The median number of induction chemotherapy cy-
cles given was 4 (range 1–4). Before high-dose chemo-
therapy, 21 patients were found eligible for PBSCR, 2 
patients refused PBSCR.
 During induction chemotherapy, nonhematologic 
toxicity was mainly mild, while no severe side effects 
(grade 3 and 4) were seen. The most frequent side effects 
were alopecia (grade 2) which was observed in all pa-
tients, and nausea (grade 1) which was seen in the ma-
jority of patients (70%). Hematologic toxicity was sig-
nificant in terms of leukopenia (30% grade 3 and 15% 
grade 4) and thrombocytopenia which occurred in al-
most every patient during the induction treatment, but 
did not differ from previously published data for doxo-
rubicin/ifosfamide chemotherapy combined with G-
CSF  [1] . 
 Response to Induction Therapy (AI-G), Stem Cell 
Collection and Surgery 
 All patients were evaluated after 4 cycles of AI-G che-
motherapy. An objective response was observed in 21 
(38%) of the 55 patients, including 3 CR and 18 partial 
responses (PR). No change was observed in 20 patients 
Table 1. Patients’ characteristics
Characteristics Patients
Sex
Male 34
Female 21
Age at entry
19–40 years 26
41–60 years 29
Site of metastases
Lung 24
Lung and liver 7
Lung and lymph node 4
Lung, liver and bone 2
Liver 4
Liver and bone 2
Lymph node 8
Bone 4
Prior treatment
None 16
Surgery alone 24
Surgery plus radiation 15
Radiation alone 0
Table 2. Histologic diagnoses and grades
Cell type Patients
grade 2 grade 3 total %
Leiomyosarcoma 6 10 16 29
Liposarcoma 3 1 4 7
Rhabdomyosarcoma 0 3 3 5
PNET 1 2 3 5
MFH 2 1 3 5
Synovial sarcoma 1 4 5 10
Hemangiopericytoma 3 2 5 10
Other 4 12 16 29
PNET = Primitive neuroectodermal tumor; MFH = malignant 
fibrous histiocytoma.
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(37%) and 14 (25%) progressed during induction therapy 
( table 3 ). All 21 patients with chemosensitive tumors re-
ceived 2 additional cycles of AI-G followed by peripheral 
blood stem cell apheresis. Collection of peripheral blood 
stem cells was achieved for these patients with a harvest 
efficiency of at least 2  ! 10 6  CD34+ cells/kg body weight. 
During mobilization chemotherapy, none of the patients 
progressed. Before high-dose chemotherapy (HD-ICE), 4 
patients underwent surgery. One patient had radical (R0) 
resection of his lung metastases. In 2 patients R0 surgery 
of their primary tumor could be obtained, and in 1 pa-
tient R1 resection of the primary tumor was achieved. 
Before the start of HD-ICE, 6 patients had no evidence of 
disease, 8 patients had only distant disease with no evi-
dence of disease at the primary tumor site and 7 patients 
entered high-dose chemotherapy with persistent disease 
at local and distant sites. 
 Toxicity and Feasibility of High-Dose Chemotherapy 
(HD-ICE) 
 Of 21 patients responding to AI-G (3 CR and 18 PR), 
19 patients received high-dose chemotherapy with PBSCR 
while 34 patients were not eligible for high-dose chemo-
therapy. Two patients being eligible for HD-ICE refused 
this treatment. HD-ICE as conditioning regimen was fea-
sible and no death due to therapy occurred. The median 
number of infused mononuclear CD34+ cells was 6  ! 
10 6 /kg body weight (range 2–12  ! 10 6 ). After HD-ICE 
chemotherapy, all patients experienced grade 3 or 4 neu-
tropenia and thrombocytopenia ( table 4 ). The maximum 
anemia seen in the trial was of grade 3, as patients received 
packed red cells before the hemoglobin decreased below 
7.5 g/dl. The median number of transfused packed red cell 
units during high-dose chemotherapy was 2 (range 0–4). 
The median duration of grade 4 neutropenia and throm-
bocytopenia was 9.3 (7–14) and 6.9 days (3–17), respec-
tively. Due to severe thrombocytopenia (grade 4), 11 pa-
tients required a median of 2 platelet transfusions (range 
1–5). Four patients suffered from severe pneumonia, 
which resolved after combined antibiotic treatment. Oth-
er infectious complications were mild, only fever of un-
known origin with a median duration of 3.5 days (0–12) 
was observed. Mucositis was severe (grade 3) in 6 patients 
requiring infusion of morphine. Hepatotoxicity with ele-
vation of bilirubin  1 3 ! N, most likely due to drug toxic-
ity, was observed in 1 patient on day 1 after PBSCR, resolv-
ing spontaneously. At a median of 13 days after PBSCR, 
patients were discharged from hospital. Up to now, with a 
median follow-up of 30 months, no late toxicity like my-
elodysplasia, leukemia or solid tumors were seen.
 Relapse and Survival  
 After a median follow-up time of 30 months, the me-
dian time to progression for the entire study group of 55 
patients was 12 months (95% CI 8–15). The 2- and 5-year 
PFS rate estimated according to Kaplan-Meier was 18% 
(95% CI 8–28) and 7% (95% CI 0–8), respectively ( fig. 1 ). 
In an intent-to-treat analysis including all 21 patients re-
sponding to AI-G induction therapy, the 2-year PFS for 
patients allocated to HD-ICE (n = 21) was 32% (95% CI 
12–52) compared to 9% (95% CI 0–18) in patients being 
treated with second-line chemotherapy after failure of 
AI-G induction (p = 0.0029). The median PFS for patients 
in the high-dose group was 16 months in contrast to the 
conventional treatment arm with a median PFS of only 7 
months ( fig. 2 ). The difference in probability of 5-year 
PFS in the high-dose group (n = 21) with 14% (95% CI 
5–47) compared to the standard treatment arm (n = 34) 
Table 3. Radiographic response to induc-
tion chemotherapy
Radiographic response Patients %
CR 3 6
PR 18 32
No change 20 37
Progressive disease 14 25
Total 55 100
Table 4. Maximal toxicity during high-dose chemotherapy (HD-
ICE; n = 18)
Patients with CTC grade toxicity
0 1 2 3 4
Leukopenia 0 0 0 3 15
Neutropenia 0 0 0 1 17
Thrombopenia 0 0 0 3 15
Anemia 0 0 5 13 0
Infection 3 1 8 6 0
Mucositis 1 3 8 6 0
Nausea 3 0 10 5 0
Nephrotoxicity               14 4 0 0 0
Hepatotoxicity 5 9 3 1 0
Neurotoxicity                 17 0 1 0 0
Cardiotoxicity                18 0 0 0 0
One patient refused further therapy after day 1 of HD-ICE. 
This patient was excluded from the toxicity evaluation. CTC = 
Common Toxicity Criteria.
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with 3% (95% CI 0–9) was statistically significant (p = 
0.003). One patient with neurofibrosarcoma and lung 
metastases being in PR after induction chemotherapy re-
fusing HD-ICE died after 39 months due to progression 
of the lung metastasis, another being in CR after induc-
tion therapy and also refusing HD-ICE, died 13 months 
after the start of the study due to progressive disease. At 
present, 7 of the 21 responding patients are alive. The 5-
year estimated OS rate of all patients is 12% with a me-
dian OS time of 22 months ( fig. 3 ). The probability of OS 
was not higher for patients responding (CR, PR) to induc-
tion chemotherapy compared to nonresponders. In an in-
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allocated to HD-ICE (n = 21) versus patients receiving conven-
tional second-line chemotherapy after failure to induction treat-
ment (no HD-ICE; n = 34; intent-to-treat analysis). 
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 Fig. 4. OS in patients responding to AI-G induction and being al-
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al second-line chemotherapy after failure to induction treatment 
(no HD-ICE; n = 34; intent-to-treat analysis). 
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tent-to-treat analysis, the median OS for the patients be-
ing allocated to high-dose chemotherapy (n = 21) was 24 
months versus 18 months for nonresponders to AI-G in-
duction. There was no statistical difference in OS be-
tween patients with stable and progressive disease (p = 
0.14). The estimated 4-year OS rate was 27% (95% CI 7–
47) for the high-dose group and 5% (95% CI 0–11) for the 
conventional treatment arm. Estimated 5-year OS in the 
2 groups did not reach the level of significance (p = 0.08; 
 fig. 4 ). 
 Discussion 
 The objective of the present study was to investigate 
efficacy in terms of OS and PFS after HD-ICE and PB-
SCR given as consolidation therapy in chemosensitive 
patients with MSTS. Therefore, HD-ICE was tested in a 
well-defined subgroup of patients experiencing CR or PR 
to AI-G chemotherapy. The design of our study is similar 
to a previously conducted study in 30 patients with ad-
vanced STS receiving high-dose chemotherapy consist-
ing of ifosfamide, etoposide and cisplatin (VIC)  [17] . The 
authors reported renal toxicity of grade 1 in 43% and 
grade 2 or higher in 20% of the patients using the VIC 
regimen. Replacing cisplatin by carboplatin in our HD-
ICE regimen was favorable with no grade 2 nephrotoxic-
ity observed. The hematologic toxicity of the HD-ICE 
regime was comparable to the VIC protocol in terms of 
duration of aplasia and number of required transfu-
sions. 
 The OS rate in our present series at 2 and 5 years is 40 
and 12%, respectively, compared to the reported OS and 
PFS rates at 5 years after high-dose chemotherapy based 
on the VIC regimen, i.e. 23 and 21%, respectively. In ad-
dition, the percentage of patients with CR before high-
dose chemotherapy was higher in the former series (27%) 
compared to our study population (6%). This is of major 
importance since the percentage of long-term survivors 
among patients with metastastic or advanced STS achiev-
ing a CR after conventional chemotherapy is a predictor 
of survival rates in a given series of patients  [4, 12, 17, 23] . 
In a large series of the EORTC Soft Tissue and Bone Sar-
coma Group including 2,185 patients with defined first-
line chemotherapy, a performance status of 0, female gen-
der and grade I histology were independent parameters 
correlating to 5-year survival besides achievement of a 
CR after first-line chemotherapy  [24] . In our study, grade 
I tumors were excluded by definition of high-risk criteria 
while most of the patients presented at an initial perfor-
mance status of 1. Furthermore, the majority of our pa-
tients were male. Also, the absence of liver metastases was 
shown to be associated with longer survival times in a 
multivariate analysis  [24] . Our study comprised 12 pa-
tients with hepatic metastases explaining an adverse sur-
vival outcome. 
 The CR rate of 6% after AI-G induction was low and 
in our study 7 patients are alive, 3 without evidence of 
disease at 37+, 47+ and 84+ months, and 4 patients with 
disease at 22+, 30+, 37+ and 43+ months. One patient 
who did not qualify for high-dose chemotherapy due to 
lack of response to AI-G chemotherapy is alive. This pa-
tient was formally diagnosed as having a gastrointestinal 
stromal sarcoma which has meanwhile been reclassified 
as a gastrointestinal stromal tumor and is now respond-
ing to treatment with imatinib.
 The present study was negative for its primary end-
point, i.e. PFS could not be prolonged from 12 to 24 
months. For the entire study population PFS was only 12 
months in accordance with previous reports and patients 
in the high-dose group showed only a slight improvement 
in PFS with 16 months. Comparing patients having re-
ceived high-dose chemotherapy with those having re-
ceived best second-line chemotherapy – although this 
non-randomized phase II study was not powered to an-
swer this question sufficiently – reveals that OS does not 
seem to be improved by high-dose chemotherapy. Only 
PFS, which is a valid endpoint for phase II studies  [25] 
was better for those patients receiving high-dose chemo-
therapy. It has to be stressed that it remains to be demon-
strated in a phase III trial whether high-dose chemother-
apy is able to improve survival of those patients who are 
in CR before high-dose chemotherapy. High-dose thera-
py has been evaluated more extensively in pediatric pa-
tients with Ewing’s sarcomas, rhabdomyosarcomas and 
osteosarcomas. Also, in this patient group several studies 
conclude that high-dose chemotherapy does not signifi-
cantly improve treatment outcome compared to conven-
tional relapse therapy  [26, 27] . Transplantation-related 
side effects and the threat of secondary malignant neo-
plasm after high-dose chemotherapy may complicate the 
future course of patients who are currently viewed as pro-
gression-free survivors  [28] . Histological subtypes which 
might benefit from dose-intensified chemotherapy should 
be selected for high-dose chemotherapy strategies. Pa-
tients with peripheral primitive neuroectodermal tumors 
were found to have a superior PFS to patients with other 
histological sarcoma subtypes  [29] . The concept of tan-
dem high-dose chemotherapy, established for other tu-
mor entities, should also be further studied for STS after 
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first pilot studies have proved the feasibility of this ap-
proach in sarcomas  [30, 31] . Our data raise the question 
whether high-dose chemotherapy and PBSCR or the in-
tensified dose of ifosfamide (12 g/m 2 ) in the ICE regime 
is responsible for the long-term survival of these patients. 
As a large number of phase II trials showed only limited 
activity of several new agents in STS  [32, 33] , a possible 
approach is to increase the CR rate to conventional che-
motherapy by escalating the dose of drugs active against 
STS. The dosage of ifosfamide in our AI-G regimen was 
suboptimal with 6 g/m 2 . Meanwhile numerous trials have 
suggested a dose-response relationship for ifosfamide  [2, 
34] . In a previous trial it was shown that multiple cycles 
of dose-intensive therapy with high-dose ifosfamide can 
be administered safely, resulting in CR rates above 20% 
 [15] . It is an open question whether the dose intensity of 
ifosfamide in our HD-ICE regimen alone warrants an ad-
vantage for patients with metastatic STS. We therefore 
plan a randomized phase III trial (high-dose ifosfamide 
vs. HD-ICE) with a larger sample size, to answer this 
question for patients with chemosensitive MSTS. 
 References 
 1 Steward WP, Verweij J, Somers R, et al: Gran-
ulocyte-macrophage colony-stimulating fac-
tor allows safe escalation of dose-intensity of 
chemotherapy in metastatic adult soft tissue 
sarcomas: a study of the European Organiza-
tion for Research and Treatment of Cancer 
Soft Tissue and Bone Sarcoma Group. J Clin 
Oncol 1993;  11:  15–21. 
 2 Le Cesne A, Judson I, Crowther D, et al: Ran-
domized phase III study comparing conven-
tional-dose doxorubicin plus ifosfamide ver-
sus high-dose doxorubicin plus ifosfamide 
plus recombinant human granulocyte-mac-
rophage colony-stimulating factor in ad-
vanced soft tissue sarcomas: a trial of the Eu-
ropean Organization for Research and 
Treatment of Cancer/Soft Tissue and Bone 
Sarcoma Group. J Clin Oncol 2000;  18:  2676–
2684. 
 3 Verweij J, Lee SM, Ruka W, et al: Random-
ized phase II study of docetaxel versus doxo-
rubicin in first- and second-line chemother-
apy for locally advanced or metastatic soft 
tissue sarcomas in adults: a study of the Eu-
ropean Organization for Research and Treat-
ment of Cancer Soft Tissue and Bone Sarco-
ma Group. J Clin Oncol 2000;  18:  2081–2086. 
 4 Blay JY, van Glabbeke M, Verweij J, et al: Ad-
vanced soft-tissue sarcoma: a disease that is 
potentially curable for a subset of patients 
treated with chemotherapy. Eur J Cancer 
2003;  39:  64–69. 
 5 Buesa JM, Mouridsen HT, van Oosterom AT, 
et al: High-dose DTIC in advanced soft-tis-
sue sarcomas in the adult: a phase II study of 
the EORTC Soft Tissue and Bone Sarcoma 
Group. Ann Oncol 1991;  2:  307–309. 
 6 Edmonson JH, Ryan LM, Blum RG, et al: 
Randomized comparison of doxorubicin 
alone versus ifosfamide plus doxorubicin or 
mitomycin, doxorubicin, and cisplatin 
against advanced soft tissue sarcomas. J Clin 
Oncol 1993;  11:  1269–1275. 
 7 Elias AD, Eder JP, Skea T, et al: High-dose 
ifosfamide with mesna uroprotection: a 
phase I study. J Clin Oncol 1990;  8:  170–178. 
 8 Nielsen OS, Judson I, van Hoesel Q, et al: Ef-
fect of high-dose ifosfamide in advanced soft 
tissue sarcomas: a multicentre phase II study 
of the EORTC Soft Tissue and Bone Sarcoma 
Group. Eur J Cancer 2000;  36:  61–67. 
 9 O’Bryan RM, Baker LH, Gottlieb JB, et al: 
Dose response evaluation of adriamycin in 
human neoplasia. Cancer 1997;  39:  1940–
1948. 
 10 Patel SR, Vadhan-Raj S, Burgess MA, et al: 
Results of two consecutive trials of dose-in-
tensive chemotherapy with doxorubicin and 
ifosfamide in patients with sarcomas. Am J 
Clin Oncol 1998;  21:  317–321. 
 11 Elias AD, Ayash LJ, Wheeler C, et al: Phase I 
study of high-dose ifosfamide, carboplatin 
and etoposide with autologous hematopoi-
etic stem cell support. Bone Marrow Trans-
plant 1995;  15:  373–379. 
 12 Dumontet C, Biron P, Bouffet E, et al: High 
dose chemotherapy with ABMT in soft tis-
sue sarcomas: a report of 22 cases. Bone Mar-
row Transplant 1992;  10:  405–408. 
 13 Kessinger A, Petersen K, Bishop M, et al: 
High dose therapy with autologous hemato-
poietic stem cell rescue for patients with 
metastatic sarcoma. Proc Am Soc Clin Oncol 
1994;  13:  1674. 
 14 Kasper B, Lehnert T, Bernd L, et al: High-
dose chemotherapy with autologous periph-
eral blood stem cell transplantation for bone 
and soft-tissue sarcomas. Bone Marrow 
Transplant 2004;  34:  37–41. 
 15 Bokemeyer C, Franzke A, Hartmann JT, et 
al: A phase I/II study of sequential, dose-es-
calated, high-dose ifosfamide plus doxorubi-
cin with peripheral blood stem cell support 
for the treatment of patients with advanced 
soft tissue sarcomas. Cancer 1997;  80:  1221–
1227. 
 16 Reichardt P, Tilgner J, Hohenberger P, 
Dorken B: Dose-intensive chemotherapy 
with ifosfamide, epirubicin, and filgrastim 
for adult patients with metastatic or locally 
advanced soft tissue sarcoma: a phase II 
study. J Clin Oncol 1998;  16:  1438–1443. 
 17 Blay JY, Bouhour D, Ray-Coquard I, et al: 
High-dose chemotherapy with autologous 
hematopoietic stem-cell transplantation for 
advanced soft tissue sarcoma in adults. J Clin 
Oncol 2000;  18:  3643–3650. 
 18 Miller AB, Hoogstraten B, Staquet M, et al: 
Reporting results of cancer treatments. Can-
cer 1981;  47:  207–214. 
 19 Trotti A, Byhardt R, Stetz J, et al: Common 
Toxicity Criteria – version 2.0: an improved 
reference for grading the acute effects of can-
cer treatment – impact on radiotherapy. Int 
J Radiat Oncol Biol Phys 2000;  47:  13–47. 
 20 Kaplan E, Meier P: Nonparametric estima-
tion from incomplete observations. J Am 
Stat Assoc 1958;  53:  457–481. 
 21 Greenwood M: The Natural Duration of 
Cancer: Reports on Public Health and Med-
ical Subjects. London, Her Majesty’s Statio-
nery Office, 1926, vol 33. 
 22 Anderson JR, Cain KC, Gelber RD: Analysis 
of survival by tumor response. J Clin Oncol 
1983;  1:  710–719. 
 23 Boulad F, Kernan NA, LaQuaglia MP, et al: 
High-dose induction chemoradiotherapy 
followed by autologous bone marrow trans-
plantation as consolidation therapy in rhab-
domyosarcoma, extraosseous Ewing’s sarco-
ma, and undifferentiated sarcoma. J Clin 
Oncol 1998;  16:  1697–1706. 
 24 Van Glabbeke M, van Oosterom AT, Ooster-
huis JW, et al: Prognostic factors for the out-
come of chemotherapy in advanced soft tis-
sue sarcoma: an analysis of 2,185 patients 
treated with anthracycline-containing first-
line regimens – a European Organization for 
Research and Treatment of Cancer Soft Tis-
sue and Bone Sarcoma Group study. J Clin 
Oncol 1999;  17:  150–157. 
 High-Dose Chemotherapy in 
Chemosensitive STS 
Oncology 2006;71:32–39 39
 25 Van Glabbeke M, Verweij J, Judson I, Nielsen 
OS; EORTC Soft Tissue and Bone Sarcoma 
Group: Progression-free rate as the principal 
end-point for phase II trials in soft-tissue 
sarcomas. Eur J Cancer 2002;  38:  543–549. 
 26 Weigel BJ, Breitfeld PP, Hawkins D, Crist 
WM, Baker KS: Role of high-dose chemo-
therapy with hematopoietic stem cell rescue 
in the treatment of metastatic or recurrent 
rhabdomyosarcoma. J Pediatr Hematol On-
col 2001;  23:  272–276. 
 27 Sauerbrey A, Bielack S, Kempf-Bielack B, 
Zoubek A, Paulussen M, Zintl F: High-dose 
chemotherapy (HDC) and autologous hema-
topoietic stem cell transplantation (ASCT) 
as salvage therapy for relapsed osteosarco-
ma. Bone Marrow Transplant 2001;  27:  933–
937. 
 28 Burdach S, van Kaick B, Laws HJ, et al: Al-
logeneic and autologous stem-cell transplan-
tation in advanced Ewing tumors: an update 
after long-term follow-up from two centers 
of the European Intergroup study EICESS. 
Stem-Cell Transplant Programs at Dussel-
dorf University Medical Center, Germany 
and St. Anna Kinderspital, Vienna, Austria. 
Ann Oncol 2000;  11:  1451–1462. 
 29 Bertuzzi A, Castagna L, Nozza A, Quagliuo-
lo V, Siracusano L, Balzarotti M, Compasso 
S, Alloisio M, Soto Parra H, Santoro A: High-
dose chemotherapy in poor-prognosis adult 
small round-cell tumors: clinical and molec-
ular results from a prospective study. J Clin 
Oncol 2002;  20:  2181–2188. 
 30 Kozuka T, Kiura K, Katayama H, et al: Tan-
dem high-dose chemotherapy supported by 
autologous peripheral blood stem cell trans-
plantation for recurrent soft tissue sarcoma. 
Anticancer Res 2002;  22:  2939–2944. 
 31 Faglioli F, Aglietta M, Tienghi A, et al: High-
dose chemotherapy in the treatment of re-
lapsed osteosarcoma: an Italian sarcoma 
group study. J Clin Oncol 2002;  20:  2150–
2156. 
 32 Van Oosterom AT, Verweij J: New drugs for 
the treatment of sarcomas. Hematol Oncol 
Clin North Am 1995;  9:  909–925. 
 33 Okuno S, Ryan LM, Edmonson JH, et al: 
Phase II trial of gemcitabine in patients with 
advanced sarcomas (E1797): a trial of the 
Eastern Cooperative Oncology Group. Can-
cer 2003;  97:  1969–1973. 
 34 Elias AD: High-dose therapy for adult soft 
tissue sarcoma: dose response and survival. 
Semin Oncol 1998;  25(suppl 4):19–23. 
 
